MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics
GENEVA, SWITZERLAND / ACCESS Newswire / December 23, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX ) (MindMaze Therapeutics or the Company), a commercial-stage company delivering evidence-based, precision digital treatments for neurological diseases, today outlined the evolution of its global reimbursement strategy to enable scalable patient access and sustainable commercial growth for next-generation neurotherapeutics. Building on […]